Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C

被引:81
作者
Mahmood, S [1 ]
Kawanaka, M [1 ]
Kamei, A [1 ]
Izumi, A [1 ]
Nakata, K [1 ]
Niiyama, G [1 ]
Ikeda, H [1 ]
Hanano, S [1 ]
Suehiro, M [1 ]
Togawa, K [1 ]
Yamada, G [1 ]
机构
[1] Kawasaki Hosp, Kawasaki Med Sch, Ctr Liver Dis, Dept Internal Med, Okayama 7000986, Japan
关键词
D O I
10.1089/152308604771978318
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidative stress (OS) plays a major role in chronic hepatitis C. Various OS markers have been found to be elevated in hepatitis C virus (HCV)-related liver disease. This study detected the presence of OS in serum and liver biopsy specimens of HCV patients. Reactive oxygen molecules (ROM) in sera of 54 HCV patients were compared with 23 controls. OS markers 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxy-2-nonenal, malondialdehyde, and thioredoxin were measured in liver biopsy specimens of 18 HCV patients with fibrosis staging F1 (six); F2 (two), F3 (four), and F4 (six). The interferon (IFN) response and hepatocellular carcinoma (HCC) occurrence in the presence of OS markers were also evaluated. The level of ROM in HCV patients was 318 +/- 56.7 Carr compared with 248 +/- 40.8 Carr in controls (p = 0.032). Multivariate analysis found age (p = 0.0236) to be the only independent variable associated with increase in ROM in sera. In liver biopsy specimens, OS markers were found mainly around the area of piecemeal necrosis or the periportal area. The presence of OS markers seemed to increase with fibrosis staging, although not significantly. The OS DNA damage marker 8-OHdG was detected in the nucleus of hepatocytes. Thirteen patients received IFN therapy. During the 4-year follow-up period, HCC developed in four nonresponders to IFN and in one untreated patient. OS markers were stained in both HCC cells and non-HCC cells in HCC patients. OS markers were found in serum and liver specimens of HCV-associated liver disease and in HCC tissue. Detection of OS markers may be important for monitoring disease progression in HCV patients. Antioxidant therapy in combination with antiviral therapy may minimize liver damage and aid in the prevention and subsequent development of HCC.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 28 条
  • [21] ODA T, 1992, CANCER RES, V52, P6358
  • [22] Paradis V, 1997, HEPATOLOGY, V26, P135
  • [23] In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features
    Paradis, V
    Mathurin, P
    Kollinger, M
    ImbertBismut, F
    Charlotte, F
    Piton, A
    Opolon, P
    Holstege, A
    Poynard, T
    Bedossa, P
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (05) : 401 - 406
  • [24] Serum malondialdehyde: Possible use for the clinical management of chronic hepatitis C patients
    Romero, MJ
    Bosch-Morell, F
    Romero, B
    Rodrigo, JM
    Serra, MA
    Romero, FJ
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1998, 25 (09) : 993 - 997
  • [25] EARLY STAGES OF MULTISTEP HEPATOCARCINOGENESIS - ADENOMATOUS HYPERPLASIA AND EARLY HEPATOCELLULAR-CARCINOMA
    SAKAMOTO, M
    HIROHASHI, S
    SHIMOSATO, Y
    [J]. HUMAN PATHOLOGY, 1991, 22 (02) : 172 - 178
  • [26] Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection
    Sumida, Y
    Nakashima, T
    Yoh, T
    Nakajima, Y
    Ishikawa, H
    Mitsuyoshi, H
    Sakamoto, Y
    Okanoue, T
    Kashima, K
    Nakamura, H
    Yodoi, J
    [J]. JOURNAL OF HEPATOLOGY, 2000, 33 (04) : 616 - 622
  • [27] Yadav D, 2002, AM J GASTROENTEROL, V97, P2634, DOI 10.1111/j.1572-0241.2002.06041.x
  • [28] IMMUNOELECTRON MICROSCOPIC OBSERVATION OF INTRAHEPATIC HBEAG IN PATIENTS WITH CHRONIC HEPATITIS-B
    YAMADA, G
    TAKAGUCHI, K
    MATSUEDA, K
    NISHIMOTO, H
    TAKAHASHI, M
    FUJIKI, S
    MIZUNO, M
    KINOYAMA, S
    TSUJI, T
    [J]. HEPATOLOGY, 1990, 12 (01) : 133 - 140